These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 37249800)

  • 21. Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease.
    Andersen NS; Donovan JW; Borus JS; Poor CM; Neuberg D; Aster JC; Nadler LM; Freedman AS; Gribben JG
    Blood; 1997 Nov; 90(10):4212-21. PubMed ID: 9354694
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.
    Andersen NS; Pedersen LB; Laurell A; Elonen E; Kolstad A; Boesen AM; Pedersen LM; Lauritzsen GF; Ekanger R; Nilsson-Ehle H; Nordström M; Fredén S; Jerkeman M; Eriksson M; Väärt J; Malmer B; Geisler CH
    J Clin Oncol; 2009 Sep; 27(26):4365-70. PubMed ID: 19652064
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HashClone: a new tool to quantify the minimal residual disease in B-cell lymphoma from deep sequencing data.
    Beccuti M; Genuardi E; Romano G; Monitillo L; Barbero D; Boccadoro M; Ladetto M; Calogero R; Ferrero S; Cordero F
    BMC Bioinformatics; 2017 Nov; 18(1):516. PubMed ID: 29169317
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of SOX11 in mantle cell lymphoma.
    Lu TX; Li JY; Xu W
    Leuk Res; 2013 Nov; 37(11):1412-9. PubMed ID: 24001358
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantitative monitoring of cyclin D1 expression: a molecular marker for minimal residual disease monitoring and a predictor of the disease outcome in patients with mantle cell lymphoma.
    Brizova H; Kalinova M; Krskova L; Mrhalova M; Kodet R
    Int J Cancer; 2008 Dec; 123(12):2865-70. PubMed ID: 18798551
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Minimal residual disease detection in mantle cell lymphoma: technical aspects and clinical relevance.
    Pott C
    Semin Hematol; 2011 Jul; 48(3):172-84. PubMed ID: 21782059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network.
    Della Starza I; Cavalli M; De Novi LA; Genuardi E; Mantoan B; Drandi D; Barbero D; Ciabatti E; Grassi S; Gazzola A; Mannu C; Agostinelli C; Piccaluga PP; Bomben R; Degan M; Gattei V; Guarini A; Foà R; Galimberti S; Ladetto M; Ferrero S; Del Giudice I;
    Hematol Oncol; 2019 Oct; 37(4):368-374. PubMed ID: 31325190
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of minimal residual disease levels with clinical outcomes in patients with mantle cell lymphoma: A meta-analysis.
    Wu X; Lu H; Pang T; Li X; Luo H; Tan H; Liu S
    Leuk Res; 2021 Sep; 108():106605. PubMed ID: 34090063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma.
    Ferrero S; Grimaldi D; Genuardi E; Drandi D; Zaccaria GM; Alessandria B; Ghislieri M; Ferrante M; Evangelista A; Mantoan B; De Luca G; Stefani PM; Benedetti F; Casaroli I; Zanni M; Castellino C; Pavone V; Petrini M; Re F; Hohaus S; Musuraca G; Cascavilla N; Ghiggi C; Liberati AM; Cortelazzo S; Ladetto M
    Blood; 2022 Sep; 140(12):1378-1389. PubMed ID: 35737911
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study.
    Cheminant M; Derrieux C; Touzart A; Schmit S; Grenier A; Trinquand A; Delfau-Larue MH; Lhermitte L; Thieblemont C; Ribrag V; Cheze S; Sanhes L; Jardin F; Lefrère F; Delarue R; Hoster E; Dreyling M; Asnafi V; Hermine O; Macintyre E
    Haematologica; 2016 Mar; 101(3):336-45. PubMed ID: 26703963
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of minimal residual disease in mantle cell lymphoma-establishment of novel eight-color flow cytometry approach.
    Chovancová J; Bernard T; Stehlíková O; Šálek D; Janíková A; Mayer J; Doubek M
    Cytometry B Clin Cytom; 2015 Mar; 88(2):92-100. PubMed ID: 25586981
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Measurable Residual Disease Monitoring in Lymphoma.
    Cuzzo B; Lipsky A; Cherng HJ
    Curr Hematol Malig Rep; 2023 Dec; 18(6):292-304. PubMed ID: 37930608
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Minimal residual disease in mantle cell lymphoma: insights into biology and impact on treatment.
    Hoster E; Pott C
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):437-445. PubMed ID: 27913513
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Detection of minimal residual diseases in B-cell tumors using PCR specific for the immunoglobulin heavy chain gene].
    Matolcsy A; Borbényi Z; Demeter J; Egyed M; Fekete S; Földi J; Gergely L; Kajtár P; Kelényi G; Kiss A; László T; Lehoczky D; Losonczy H; Nagy M; Pál K; Pálóczy K; Radványi G; Semsei I; Varga G; Udvardy M
    Orv Hetil; 2000 Jun; 141(25):1403-6. PubMed ID: 10934884
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group.
    Le Bris Y; Magrangeas F; Moreau A; Chiron D; Guérin-Charbonnel C; Theisen O; Pichon O; Canioni D; Burroni B; Maisonneuve H; Thieblemont C; Oberic L; Gyan E; Pellat-Deceunynck C; Hermine O; Delfau-Larue MH; Tessoulin B; Béné MC; Minvielle S; Le Gouill S
    Hematol Oncol; 2020 Oct; 38(4):446-455. PubMed ID: 32472610
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SOX11, CCND1, BCL1/IgH and IgH-VDJ: a battle of minimal residual disease markers in mantle cell lymphoma?
    Simonsen AT; Schou M; Sørensen CD; Bentzen HH; Nyvold CG
    Leuk Lymphoma; 2015; 56(9):2724-7. PubMed ID: 25629991
    [No Abstract]   [Full Text] [Related]  

  • 37. Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes.
    Yalniz FF; Patel KP; Bashir Q; Marin D; Ahmed S; Alousi AM; Chen J; Ciurea SO; Rezvani K; Popat UR; Shpall EJ; Champlin RE; Oran B
    Cancer; 2020 May; 126(10):2183-2192. PubMed ID: 32101640
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitative assessment of minimal residual disease (MRD) in canine lymphoma by using real-time polymerase chain reaction.
    Yamazaki J; Baba K; Goto-Koshino Y; Setoguchi-Mukai A; Fujino Y; Ohno K; Tsujimoto H
    Vet Immunol Immunopathol; 2008 Dec; 126(3-4):321-31. PubMed ID: 18977540
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted Locus Amplification as Marker Screening Approach to Detect Immunoglobulin (IG) Translocations in B-Cell Non-Hodgkin Lymphomas.
    Genuardi E; Alessandria B; Civita AM; Ferrero S
    Methods Mol Biol; 2022; 2453():119-132. PubMed ID: 35622324
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of Immunoglobulin Heavy Chain Gene Clonality by Next-Generation Sequencing for Minimal Residual Disease Monitoring in B-Lymphoblastic Leukemia.
    Shin S; Hwang IS; Kim J; Lee KA; Lee ST; Choi JR
    Ann Lab Med; 2017 Jul; 37(4):331-335. PubMed ID: 28445014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.